Author name: Ying Mak

Digital measures to advance research & quality of life in schizophrenia

/ eBooks & Whitepapers, Publications & posters

Schizophrenia spectrum disorders are complex and serious psychiatric disorders with multifaceted symptoms and associated difficulties, including psychosis, negative symptoms (e.g., loss of motivation), cognitive dysfunction, and functional impairment in major life areas. This multifaceted clinical picture in schizophrenia is also heterogeneous, both across individuals and within individuals over time, posing a challenge for studying groups […]

Digital measures to advance research & quality of life in schizophrenia Read More »

Prediction of mental effort derived from an automated vocal biomarker using machine learning in a large-scale remote sample

/ Publications & posters

Biomarkers of mental effort may help to identify subtle cognitive impairments in the absence of task performance deficits. Here, we aim to detect mental effort on a verbal task, using automated voice analysis and machine learning. Nick Taptiklis, Merina Su, Jennifer H. Barnett, Caroline Skirrow, Jasmin Kroll, Francesca Cormack  Audio data from the digit span

Prediction of mental effort derived from an automated vocal biomarker using machine learning in a large-scale remote sample Read More »

Digital Biomarkers & Alzheimer’s Research: Q&A with Liam Kaufman, VP of Clinical Sciences

/ Insights

Kaufman discusses the ways the digital biomarkers are improving Alzheimer’s research by directly tackling some of the unique challenges that researchers face. by Mike HollanOriginally published on PharmExec.com Researching and developing treatments for Alzheimer’s disease comes with unique challenges, due to the nature of the disease. Liam Kaufman, VP of clinical sciences at Cambridge Cognition, spoke

Digital Biomarkers & Alzheimer’s Research: Q&A with Liam Kaufman, VP of Clinical Sciences Read More »

Cambridge Cognition and ActiGraph announce partnership to accelerate central nervous system trials

/ News

by ActiGraph PENSACOLA, FL, February 20, 2024 – ActiGraph and Cambridge Cognition, leading providers of wearable digital health technologies and CNS assessments, respectively, announced a new strategic partnership to deliver a broad suite of assessments to provide a fully-rounded view of mental and physical capabilities. The companies’ technologies have been used together by top 20

Cambridge Cognition and ActiGraph announce partnership to accelerate central nervous system trials Read More »

Technology for successful decentralised clinical trials

/ Insights

The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality.  At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog

Technology for successful decentralised clinical trials Read More »

Success Factors for Remote and Hybrid Decentralised Trials from Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home

/ Webinars

Success Factors for Remote and Hybrid Decentralised Trials From Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home About this webinar Thursday 16th November 2023 10:00-11:00 EST | 15:00-16:00 GMT Platform: Zoom Webinars Amidst the enthusiasm surrounding the advantages and efficiencies promised by Decentralised Clinical Trials (DCTs), encompassing remote

Success Factors for Remote and Hybrid Decentralised Trials from Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home Read More »

Launch of automated quality assurance for clinical trials

/ News

News Back to resource centre 24 October 2023 Launch of automated quality assurance for clinical trials Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the launch today of AQUA, the Company’s automated quality assurance solution for central nervous system (“CNS”) clinical trials that is powered

Launch of automated quality assurance for clinical trials Read More »

Why don’t we trust people’s lived-experience of fatigue?

/ Insights

Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is

Why don’t we trust people’s lived-experience of fatigue? Read More »

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease

/ Insights

A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.

Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease Read More »

Highlights from AAIC 2023

/ Insights

The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.

Highlights from AAIC 2023 Read More »

Cambridge Cognition
Scroll to Top